AI assistant
Sending…
CervoMed Inc. — Director's Dealing 2022
Aug 26, 2022
34364_dirs_2022-08-26_efbdc6d4-6263-4a40-b030-e3d43868e077.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Diffusion Pharmaceuticals Inc. (DFFN)
CIK: 0001053691
Period of Report: 2022-05-18
Reporting Person: JAEGER RAVEN (Chief Regulatory Officer)
More from CervoMed Inc.
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Apr 22
Regulatory Filings
2026
Mar 19
Regulatory Filings
2026
Mar 17
Regulatory Filings
2026
Feb 18
Director's Dealing
2026
Feb 13
Director's Dealing
2026
Feb 13
Director's Dealing
2026
Feb 13
Director's Dealing
2026
Feb 13